All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the major advances for the triple-class exposed population?

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Maria-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, What are the major advances for the triple-class exposed population?

What are the major advances for the triple-class exposed population?

In this video, Mateos discusses the major advances in treatment for triple-class exposed patients with multiple myeloma, including melflufen, selinexor, and B-cell maturation antigen chimeric antigen receptor T-cell therapy.

 

Share: